SOURCE: CLX Medical, Inc.

April 25, 2008 10:28 ET

CLX Medical, Inc. Releases April 2008 Newsletter Highlighting New Corporate Name and Targeted Acquisition in the Medical Diagnostic Testing Market

MURRIETA, CA--(Marketwire - April 25, 2008) - CLX Medical, Inc. (OTCBB: CLXN), which is focused on the launch and distribution of unique medical diagnostic testing products, today issued its April 2008 investor newsletter, which reviews the company's recent name change to CLX Medical and the announcement of a new targeted acquisition in the medical diagnostic testing market.

A PDF version of the April 2008 newsletter can be viewed on the company's corporate website at

The newsletter highlights additional CLX events from the last month, including the identification of and negotiations with a major European distributor to serve as the sole importer of CLX's subsidiary products into the European market. The master distributor will provide product support and product packaging control; coordinate sales to other European distributors; distribute products in its own territory; act as the registered EU representative for CE marked products; and assist with the development and implementation of pricing structures.

CLX currently holds a majority interest in Zonda, Incorporated, a developer and manufacturer of unique diagnostic tests, including a rapid point of care test for chlamydia. Zonda's chlamydia product has been distributed in Europe for approximately three years.

Another newsletter article concerns the selection of IIT Research Institute (IITRI) to serve as the laboratory that will conduct a validation study for Zonda's rapid point of care test for chlamydia. A major purpose of the validation study is to perfect the testing protocol in preparation for the clinical trials as part of the process to achieve FDA clearance for the product.

In addition to Zonda's chlamydia product, CLX recently announced that the company has identified a rapid diagnostic device for the medical market that it has targeted for potential acquisition. As additional due diligence and negotiations are undertaken, the company expects to enter into an initial agreement in the form of a letter of intent for the acquisition of the device.

"Each of the events discussed in this month's newsletter are directly tied to the core focus of CLX: to become a leader in the distribution of rapid medical diagnostic testing products," stated Vera Leonard, chief executive officer of Zonda and CLX. "We are very pleased to see progress in virtually every area of the business, and we expect to continue to move forward on all fronts in the coming weeks."

To sign up to receive information by email directly from CLX Medical, Inc. when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit

About CLX Medical, Inc.

CLX Medical, Inc. ( holds a 51% equity interest in Zonda, Inc. CLX has also invested, and holds a common stock position, in ActionView International, Inc. (, a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Medical, inc. are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Medical's control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

Contact Information

  • Contact:
    Gemini Financial Communications, Inc.
    A. Beyer
    Email Contact